Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rivaroxaban review scheduled

Executive Summary

The Cardiovascular and Renal Drugs Advisory Committee will meet March 19 to review Johnson & Johnson/Bayer's novel factor Xa inhibitor Xarelto (rivaroxaban) for prophylaxis of deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery, FDA announces. The NDA has a PDUFA date of May 29, 2009. The application is based on four Phase III studies - known as RECORD 1-4 - involving more than 12,500 patients (1"The Pink Sheet" DAILY, July 30, 2008). Bayer launched the oral anticoagulant in Europe in October 2008

You may also be interested in...



With European Approval Imminent, J&J/Bayer File Rivaroxaban In The U.S.

Novel anticoagulant for orthopedic surgery poised to reach market before Pfizer, Bristol, Astellas and Daiichi Sankyo compounds.

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel